Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia
ABSTRACT Introduction Pulmonary hypertension (PH) is a chronic disease characterized by a progressive rise in pulmonary artery blood pressure. The objective was to describe the treatment patterns among ambulatory patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonar...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.70063 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850078087814840320 |
|---|---|
| author | Manuel Machado‐Duque Andrés Gaviria‐Mendoza Luis Fernando Valladales‐Restrepo Manuel Pacheco Juan Sebastián Franco María delRosario Forero Rubiela Suarez Oscar Peñuela Jorge E. Machado‐Alba |
| author_facet | Manuel Machado‐Duque Andrés Gaviria‐Mendoza Luis Fernando Valladales‐Restrepo Manuel Pacheco Juan Sebastián Franco María delRosario Forero Rubiela Suarez Oscar Peñuela Jorge E. Machado‐Alba |
| author_sort | Manuel Machado‐Duque |
| collection | DOAJ |
| description | ABSTRACT Introduction Pulmonary hypertension (PH) is a chronic disease characterized by a progressive rise in pulmonary artery blood pressure. The objective was to describe the treatment patterns among ambulatory patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in a real‐world setting. Methods This is a longitudinal cohort follow‐up study characterizing the treatment patterns of patients diagnosed with PAH or CTEPH, with secondary data from a population‐based drug‐dispensing database between 2022 and 2023, which includes sociodemographic, diagnosis, prescribing specialty, and treatment (drugs, persistence of use, and concomitant medications). Results In total, 1045 patients with a diagnosis of PH were identified, with mean age of 62.9 ± 18.2 years, and 72.3% of females; of which 947 (90.6%) received monotherapy, and 98 (9.4%) received combination therapy at the beginning of follow‐up. The most frequently used drugs for the treatment of PH were calcium channel blockers (58.1%), followed by phosphodiesterase 5 inhibitors (41.1%), endothelin receptor antagonist (32.5%), and guanylate cyclase stimulants (9.7%). The schemes used most frequently were monotherapy with amlodipine (31.0%), sildenafil (19.2%), or nifedipine (10.0%), but the main combination were sildenafil with nifedipine (2.5%). The mean of persistence of use was 161 ± 123 days during 1 year of follow‐up. Conclusions This group of patients with PH from Colombia were treated predominantly with monotherapy of calcium channel blockers and phosphodiesterase 5 inhibitors. However, current clinical practice guidelines recommend the use of combined therapy. The average persistence of the use of drugs for treatment for less than 6 months may be associated with difficulties in follow‐up, adherence, effectiveness, tolerability, and access. |
| format | Article |
| id | doaj-art-1f9010c8f40e49b3b57c0bb5a9f6b8b1 |
| institution | DOAJ |
| issn | 1752-6981 1752-699X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Clinical Respiratory Journal |
| spelling | doaj-art-1f9010c8f40e49b3b57c0bb5a9f6b8b12025-08-20T02:45:38ZengWileyThe Clinical Respiratory Journal1752-69811752-699X2025-02-01192n/an/a10.1111/crj.70063Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in ColombiaManuel Machado‐Duque0Andrés Gaviria‐Mendoza1Luis Fernando Valladales‐Restrepo2Manuel Pacheco3Juan Sebastián Franco4María delRosario Forero5Rubiela Suarez6Oscar Peñuela7Jorge E. Machado‐Alba8Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia Universidad Tecnológica de Pereira y Audifarma S.A Pereira ColombiaGrupo de Investigación en Farmacoepidemiología y Farmacovigilancia Universidad Tecnológica de Pereira y Audifarma S.A Pereira ColombiaGrupo de Investigación en Farmacoepidemiología y Farmacovigilancia Universidad Tecnológica de Pereira y Audifarma S.A Pereira ColombiaUniversidad Tecnológica de Pereira Pereira ColombiaMedical Affairs, Bayer S.A. Bogotá ColombiaMedical Affairs, Bayer S.A. Bogotá ColombiaMedical Affairs, Bayer S.A. Bogotá ColombiaMedical Affairs, Bayer S.A. Bogotá ColombiaGrupo de Investigación en Farmacoepidemiología y Farmacovigilancia Universidad Tecnológica de Pereira y Audifarma S.A Pereira ColombiaABSTRACT Introduction Pulmonary hypertension (PH) is a chronic disease characterized by a progressive rise in pulmonary artery blood pressure. The objective was to describe the treatment patterns among ambulatory patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in a real‐world setting. Methods This is a longitudinal cohort follow‐up study characterizing the treatment patterns of patients diagnosed with PAH or CTEPH, with secondary data from a population‐based drug‐dispensing database between 2022 and 2023, which includes sociodemographic, diagnosis, prescribing specialty, and treatment (drugs, persistence of use, and concomitant medications). Results In total, 1045 patients with a diagnosis of PH were identified, with mean age of 62.9 ± 18.2 years, and 72.3% of females; of which 947 (90.6%) received monotherapy, and 98 (9.4%) received combination therapy at the beginning of follow‐up. The most frequently used drugs for the treatment of PH were calcium channel blockers (58.1%), followed by phosphodiesterase 5 inhibitors (41.1%), endothelin receptor antagonist (32.5%), and guanylate cyclase stimulants (9.7%). The schemes used most frequently were monotherapy with amlodipine (31.0%), sildenafil (19.2%), or nifedipine (10.0%), but the main combination were sildenafil with nifedipine (2.5%). The mean of persistence of use was 161 ± 123 days during 1 year of follow‐up. Conclusions This group of patients with PH from Colombia were treated predominantly with monotherapy of calcium channel blockers and phosphodiesterase 5 inhibitors. However, current clinical practice guidelines recommend the use of combined therapy. The average persistence of the use of drugs for treatment for less than 6 months may be associated with difficulties in follow‐up, adherence, effectiveness, tolerability, and access.https://doi.org/10.1111/crj.70063calcium channel blockersendothelin receptor antagonistspulmonary hypertensionpharmacoepidemiologyphosphodiesterase 5 inhibitors |
| spellingShingle | Manuel Machado‐Duque Andrés Gaviria‐Mendoza Luis Fernando Valladales‐Restrepo Manuel Pacheco Juan Sebastián Franco María delRosario Forero Rubiela Suarez Oscar Peñuela Jorge E. Machado‐Alba Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia The Clinical Respiratory Journal calcium channel blockers endothelin receptor antagonists pulmonary hypertension pharmacoepidemiology phosphodiesterase 5 inhibitors |
| title | Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia |
| title_full | Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia |
| title_fullStr | Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia |
| title_full_unstemmed | Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia |
| title_short | Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia |
| title_sort | treatment patterns of patients with pulmonary hypertension a descriptive study in colombia |
| topic | calcium channel blockers endothelin receptor antagonists pulmonary hypertension pharmacoepidemiology phosphodiesterase 5 inhibitors |
| url | https://doi.org/10.1111/crj.70063 |
| work_keys_str_mv | AT manuelmachadoduque treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT andresgaviriamendoza treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT luisfernandovalladalesrestrepo treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT manuelpacheco treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT juansebastianfranco treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT mariadelrosarioforero treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT rubielasuarez treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT oscarpenuela treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia AT jorgeemachadoalba treatmentpatternsofpatientswithpulmonaryhypertensionadescriptivestudyincolombia |